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Ninety-three primary malignant melanomas of the 
skin were typed immunohistologically for the expres-
sion of HLA-DR on tumor cells. HLA-DR-positive 
stroma cells were found in all specimens, whereas the 
melanoma cells were HLA-DR-negative or only locally 
positive in most cases. In 36 (39%) of the lesions more 
than 10% of the tumor cells were stained by two mono-
clonal antibodies against the nonpolymorphic portion of 
HLA-DR. HLA-DR-positive tumor cells were often ac-
cumulated at the advancing front of the melanoma. The 
occurrence of HLA-DR-positive tumor cells was related 
to tumor thickness and level of invasion. Substantial 
numbers of HLA-DR-positive tumor cells were found in 
half of the tumors thicker than 1.5 mm and in only 18% 
of flatter .lesions. The highest percentage of HLA-DR-
pos itive tumors was found in the group of melanomas 
invading the reticular dermis (level IV). The majority 
of tumors (18/24) that had metastasized within an ob-
servation period of 0-32 months were HLA-DR-posi-
tive. Regarding the mononuclear cell infiltrate, no cor-
relation between the degree of overall infiltrate and the 
expression of HLA-DR by the tumor cells was found. 
The infiltrate within the tumor, however, was more 
often marked in HLA-DR-positive than in HLA-DR-
negative melanomas. 
Cellular in te ractions during immune response in huma ns 
requ ire t he expression of l a- like molecules (HLA-DR) on the 
cell surface [1). HLA -DR m olecul es were first discovered on B 
lymphocytes a nd monocytes [2], but HLA-DR can a lso be 
exp ressed by va rious n ormal cells, such as vascular endothelium 
[3], activated T lymphocytes [4], epidermal cells [5], a nd var-
ious tumor cells, including m a ligna n t melanoma [6- 9) . The 
presence of HLA-DR on mela noma cells is thought to be 
necessary for the initiation of an autologous immune response 
[1 0]. In spite of the undoubted exp ression of HLA-DR by a 
great part of established melanoma cell lines, divergent results 
we re published co nce rnin g t he in vivo expression [11- 14) . We 
the refo re typed our biopsy material of 93 primary melanomas 
of t he sk in for t he in situ occurrence of HLA-DR on tumor 
cells . In 39% of t he lesions substant ia l numbers of HLA-DR-
posit ive t umor cells were found. H owever, not a ll tumor cells 
stained positive. A re lation became apparent between the 
express ion of HLA-DR to level of invasion [15], tumor thick-
ness [ 16], density of in t ratumora l mononuclear cell infiltrate, 
a nd incidence of early metastases. 
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Abb reviations: 
AEC: 3-amino-9-ethylcarbazole 
LMM: lentigo maligna melanoma 
MoAb: monoclonal antibody 
NM: nodular melanoma 
SSM: superficial spreading melanoma 
MATERIALS AND METHODS 
Monoclonal Antibodies (MoAb) and Reagents 
0Kla1 was purchased from Ortho Pharmaceutical , Raritan, New 
J ersey. Monoclonal antibody (MoAb) 910D7 was raised by immuniza-
t ion of mice with human monocytes (U. Feige et al, 1983, in prepara-
t ion) and is directed against the nonpolymorphic portion of HLA-DR, 
which is found on 20- 80% of monocytes of various donors and on 100% 
of cells of 10-day-old cultures of human macrophages. MoAb 910D7 
immunoprecipi tates a 29 and a 34 kilodalton protein from Daudi cells. 
The staining pattern of 910D7 in tissue sections was similar to 0Kia1 
in more than 100 specimens tested previously. Normal goat serum and 
goat antimouse lgG, conjugated with horseradish peroxidase, was pur-
chased from Medac Hamburg, F.R.G., 3-amino-9-ethylcarbazole (AEC) 
from Sigma (Munich), hemalaun and methylgreen from Merck, 
(Darmstadt), and Aquamount from BDH Chemical Ltd., London. 
Tissue Samples 
A portion of excision biopsies of 93 primary melanomas was snap-
frozen in liquid nitrogen and stored at - so·c. The remaining part of 
the t issues was used in routine histologic procedures to ascertain 
histopathologic diagnosis, assessment of tumor thickness [16], and 
level of invas ion [15]. For immunohistologic examinations a tumor 
port ion close to the thickest part was chosen. 
lmmu.n.operoxidase Technique 
Cryostat sections of 5- 7 !Lm thickness were stained with the indirect 
peroxidase techn ique as described previously [17]. 
Evaluation. 
Counterstaining with methylgreen, which was used in pigmented 
lesions in addi t ion to hemalaun, turned melanin pigment in to a green-
brown product, t hus allowing its easy distinction from the red reaction 
product of AEC. Positive reactions with tumor cells were scored as 
percent positive per total number of tumor cells. Positive reactions 
with other cells, such as lymphocytes, macrophages, endothelium, and 
fibrobl asts were determined as well. Evaluations were performed by 
two independent observers (E.-B.B. and L.S.) Tumors were noted 
"substantially positive" when the percentage of stained cells within the 
melanoma nests exceeded 10%, or when clusters of tumor cells were 
stained. 
Assessment of the Mon.on.uclea.r Cell Infiltrate 
The mononuclear cell infil t rate was graded arbitrari ly from 0 (no 
cells) to 3 (marked infiltrate) at different locations around and within 
the tumors, as recently described [18]. The determination of t he infil-
trate pattern in melanomas, was done independently from the immu-
nohistologic investigation. Routine histologic paraffin sections of the 
tumors were evaluated and the density of infiltrate within the tumors 
and the density of infil t rate beneath and at the edges of tumors were 
graded separate ly. 
RESULTS 
Ninety-three primary melanomas of the s kin were typed for 
HLA-D R. Fifty-s ix tumors were stained with 0Kla1, 87 with 
MoAb 910D7, 53 with both a ntibodies. In 36 (39%) tumors 
more than 10% of HLA-DR-pos itive tumor cells were found. 
T hese tumors were noted "substantia lly HLA-DR-positive." 
Staining of t umor cells was cytoplasmatic in all pos itive les ions 
and appeared a lso membrane-bound in most cases. No mela-
noma revealed 100% of HLA-DR-positive tumor cells, a nd in 
only 9 lesions more than 50% of tumor cells were stained. 
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Clusters of HLA-DR-positive tumor cells were often observed 
at the advancing front of the melanoma (Fig 1) and occasionally 
at t he epidermal-coria! junction. HLA-DR-positive stroma 
cells, as lymphocytes, macrophages, endothelium, and fibro-
blasts, were present in all cases. 
Table I shows the frequencies of HLA-DR-positive tumors 
according to the histologic type. A wide range of the percentage 
of stained cells in tumors noted "posit ive" was fou nd through-
out. The frequency of HLA-DR-positive lesions was found to 
be similar in nodular melanoma (NM) and superficial spreading 
me lanoma (SSM) and lower in lentigo maligna melanoma 
(LMM), but t his was statistically insign ificant. 
In Table II, the distribution of tumors according to level of 
invasion [15] and expression of HLA-DR is shown. The highest 
percentage of HLA-DR-positive tumors was found in level IV 
melanomas (p < 0.05). 
In Table III, the relation of HLA-DR expression to tumor 
thickness (16) is shown. Tumors thicker than 1.5 mm were 
HLA-DR-positive in approximately 50% of the cases, whereas 
t his was significantly less often observed in t hinner lesions ( p 
< 0.01) . Table III shows also the relation to cl inical data. 
Fifteen of 84 stage I patients developed metastases within t he 
observation period of 3-32 month, 9 patients were stage II at 
the time of primary treatment. The majority (18/24) of metas-
tasizing primary melanomas were HLA-DR-positive. In tumors 
t hinner than 3 mm, more than in thicker tumors, the incidence 
of early metastases was increased in HLA-DR-positive, com-
pared to HLA-DR-negative cases. 
In 61 melanomas t he mononuclear cell infiltrate was studied 
in the routine histologic sections, and the results were compared 
FIG 1. SSM, Clark level IV, 1.58 mm thickness. HLA -DR-negative 
melanoma cell nests (m) are present in the upper portion and HLA-
DR-positive melanoma cel l nests in the deeper portion of the tumor. 
T he mononuclear ce ll infiltrate (i) at the base of the melanoma is 
markedly stained for HLA-DR (MoAb 0Kla1, with hemalaun counter-
staining, X 80). 
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TABLE I. HLA-DR expression and histologic type 
Substantially HLA· Range of 
Type Range of tumor OR-positive positive-stain-
thickness (mm) tumors/all tumo rs ing tumo r ce lls 
(perce ntage) (percentage) 
ALM 4.5 0/1 
MM unclassified 1.2, 5. 7 1/2 80 
LMM 0.4-15 2/11 (18) 20- 25 
NM 1.8- 5.8 4/9 (44) 20- 50 
SSM 0.24- 8.9 29/70 (41) 10- 80 
TABLE II. HLA -DR expression and level of invasion 
Clark level 
II 
III 
IV 
v 
Substantially HLA-DR-positive tumors/ a ll 
tumors (pe rcen t.age) 
0/5 
9/34 (26) 
21/39 (54) 
6/15 (40) 
TABLE III . HLA -DR expression, tumor thickness, and incidence of 
early metastases 
Number of metastatic cases and cases with 
Tumor 
considerable HLA-DR exp ression 
Percentage of 
thickness HLA -DR positive HLA-DR negative HLA-DR positive (mm) 
Without With cases Without With 
mel.ast. metast. met.ast. metast.. 
<1.5 5 2 32 0 18 
1.5- 3 9 8 11 1 59 
>3 4 8 8 5 48 
TABLE IV . HLA -DR expression and mononuclear cell infiltrate at 
different locations 
Substantially 
HLA-DR-positive 
tumors 
n = 23 
HLA-DR- negative 
or only locally 
positive tumors 
n = 38 
Infiltrate beneath and at Mononuclear infiltrate 
the sides of tumors within the tumors 
I nt.er- Inter· 
No/sparse mediate/ No/sparse mediate/ 
marked marked 
12 (52%) 11 (48%) 8 (35%) 15 (65%) 
18 (47%) 20 (53 %) 29 (76%) 9 (24 %) 
with the results from staining for HLA-DR. Table IV shows 
~h~t no correlation between HLA-DR expression and degree of 
mhltrate could be obtained when the mononuclear cell infil-
trate beneath and the edges of tumors was considered. However, 
HLA-DR-positive melanomas revealed more often increased 
numbers of mononuclear cells within the tumor than did HLA-
DR-negative melanomas. 
DISCUSSION 
The in situ presence of HLA-DR antigen on melanoma cells 
has been studied immunohistologically in a large group of 
pnmary melanomas of the skin. Thirty-six of 93 tumors were 
noted HLA-DR-positive, i.e., more than 10% of tumor cells 
were stained wi th MoAbs against HLA-DR. In most cases, 
however, only t he smaller portion of tumor cells in a repre-
sentative section was stained. Those HLA-DR-posit ive tumor 
cells often were accumulated at the invasive front of the tumors 
and occasionally at the epidermal-coria! junction. The fre~ 
quency of HLA-DR-positive melanomas is higher than in a 
previous study [13] and lower than reported by Thompson et 
al [ll) . Our results are in concordance with Natali et al [14). 
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who found HLA-DR-positive and HLA-DR-negative primary 
tumors within 4 metastasizing NM, and with Ruiter et a l [19], 
who, using a panel of MoAbs directed against different epitopes 
of HLA-DR, recently showed t hat t he discrepancies in t he 
literature are probably not caused by t he specificities of MoAbs. 
The latter authors found HLA-DR-positive t umor cells in 7/13 
primary melanomas, but t he percentage of positive cells was 
less t han 5% in some cases. We noted such tumors positive 
where more t han 10% of tumor cells were stained with MoAbs 
against HLA-DR. 
HLA-DR-negative tumor cell nests can be surrounded by 
strongly HLA-DR-positive fibroblast-shaped cells. Staining of 
some tumo r cells close to these cells was not infrequent ly 
observed in melanomas where the great majority of tumor cells 
were not stained. Single, large, HLA-DR-positive cells were 
found withi n clusters of HLA-DR-negative t umor cells as well. 
In a previous study [20] we found such cells positive for non -
spec ific esterase, suggesting that t hey were macrophages. In 
th is study we tried to ascertain our eva luation by staining seria l 
sections with anti-HLA-DR MoAbs, with t he M oAb M-2-2-4 
[17], which sta ins mela noma cells but no macrophages, and 
with the MoAb 25 F9 [21], which reacts strongly with cyto-
p lasmatic structures of melanoma-infiltrating macrophages. By 
this approach, it was possible to confirm that cell clusters were 
melanoma cells, expressing both HLA-DR and M-2-2-4 ant i-
gens . However, single HLA-DR-positive cells within negative 
tumor cell nests could be identified in t he same section only by 
a double-staining procedure which we did not apply. The in-
tense s taini ng with MoAb 25F9 allowed the identification of 
macrophages within melanoma infiltrates. H oweve r, since ap-
proximately one~ third of melanomas uniformly expressed, 
though less intensively, the structure recognized by MoAb 25F9, 
independently whether the tumor cells expressed HLA-DR or 
not, this MoAb was less helpfu l t han expected for a clear-cut 
discrimination between tumor cells and macrophages. 
An in teresting finding is t he increased frequency of HLA-
DR-positive tumor cells in th icker melanomas. This was men-
t ioned recently by Ruiter et al [19], who investigated a smalle r 
group of primary melanomas. In ou r study, the rate of HLA-
DR-positive tumors is low in level II and III lesions (9/39) and 
high (21/39) in melanomas that have penetrated into t he retic-
ular dermis (level IV). Interestingly, no furt her increment of 
the frequency of HLA-DR-positive tumors was observed in 
tumors t hat have invaded into t he subcutaneous fat (level V), 
but rather a decrement. Similar ly, very th ick melanomas (> 3 
mm) were slightly less frequently substantially HLA-DR-posi-
tive t han tumors 1.5- 3 mm in t hickness. This observation , 
which has to be confirmed in a larger series of t umors , raises 
the question of whether HLA-DR expression may be a t ransient 
p henomenon during loca l tumor progression. 
Regarding the incidence of metastases, which were found 
either at t he time of primary treatmen t (stage II patients) or 
appea red within t he short observation t ime of 3- 32 months, 
HLA-DR expression by melanoma cells appears to be related 
with an increased risk of metastasis, especia lly in t he group of 
tumo rs t hinner t han 3 mm. 
In many HLA-DR-positive tumors, increased numbers of 
mononuclear cell s were found in close contact with tumor cells. 
T his was less freq uently observed in HLA-DR-negative tumors. 
The degree of mononuclear cell infil t rate located more distant 
from the tumor cells apparently was not correlated with t he 
expression of HLA-DR on the tumor cells. 
T he signi ficance of !a-antigens in t he induction of immune 
response has been shown in many instances [1 ,3). The biologic 
role of !a-like antigens on melanoma cells is not clear from t he 
available information, since HLA-DR-positive and -negative 
tumor cells can be found at any stage of t he disease [10,14, 
unpublished observation]. 
From the data shown above, HLA-DR expression in primary 
melanomas does not seem to co rrelate with a favo rable prog-
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nosis, but rather wit h the contrary. Therefore, t he question 
remains open , in what way t he immune system and t he expres. 
sion of HLA-DR antigen by tumor cells is functional in the 
course of tumor progression. F urthermore, it is an open ques-
tio n, whether HLA-DR expression by tumor cells is attractino 
mononuclear cell infil trates, or whether t he infiltrating cell~ 
a re inducing t he expression of HLA-DR an t igen in melanoma 
cells by mechanisms which have been recently investigated 
[22,23]. 
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